Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

Ipek Yonal-Hindilerden 1, Fehmi Hindilerden 2, Metban Mastanzade 1, Tarik Onur Tiryaki 1, Sevim Tasan-Yenigun 3, Yusuf Bilen 4, Selcuk Aksoz 5, Arif Atahan Cagatay 6 and Meliha Nalcaci 1

1 Division of Hematology, Department of Internal Medicine, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey, 2 Hematology Clinic, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey, 3 Department of Chest Disease, Adiyaman University Medical Faculty, Adiyaman, Turkey, 4 Division of Hematology, Department of Internal Medicine, Adiyaman University Medical Faculty, Adiyaman, Turkey, 5 Department of Infectious Diseases and Clinical Microbiology, Adiyaman University Medical Faculty, Adiyaman, Turkey, 6 Department of Infectious Diseases and Clinical Microbiology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes from this viral infection due to the immunosuppression brought about by the underlying cancer and the effects of therapy. We present a 55-year-old woman diagnosed with relapsed/refractory Hodgkin’s lymphoma (HL) who had been heavily pretreated with multiagent chemotherapy, autologous hematopoietic stem cell transplantation (autoHCT), allogeneic hematopoietic stem cell transplantation (alloHCT) and was complicated with EBV associated posttransplant lymphoproliferative disease (PTLD) and chronic graft-versus-host-disease (GVHD). The patient was recently treated with brentuximab and donor lymphocyte infusion (DLI) for relapse after alloHCT. She suffered from severe COVID-19 pneumonia and eventually succumbed to acute respiratory distress syndrome (ARDS) and multiorgan failure. Of note, this is the first reported case of COVID-19 in a HL patient who was being treated with brentuximab for relapse after alloHCT.

Keywords: coronavirus disease 2019, Hodgkin’s lymphoma, brentuximab, donor lymphocyte infusion, allogeneic stem cell

INTRODUCTION

In December 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China (1). This novel coronavirus was named as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In February 2020, the World Health Organization (WHO) designated the disease coronavirus disease 2019 (COVID-19). Many studies have identified cancer as a comorbidity in COVID-19 patients. The study by Liang et al., which included 1,590 COVID-19 cases, demonstrated that the likelihood of COVID-19 infection was higher in cancer patients with an increased risk of severe outcomes compared to non-cancer patients.
patients compared to the normal population (2). In addition, among cancer patients, the incidence of the need for intensive level care, mechanical ventilation and potential deaths are higher compared to non-cancer patients (2). Immunocompromised patients with hematologic cancers have been historically more susceptible to viral respiratory diseases. That risk is currently more apparent given the increased virulence of the severe SARS-CoV-2 (3, 4). One multicenter study including 105 patients with cancer showed that cancer patients are at higher risk for COVID-19 and encounter a higher frequency of severe events. Moreover, patients with hematologic malignancies such as lymphoma were noted to have relatively higher rates of death, intensive care unit (ICU) admission, and requirement for invasive mechanical ventilation (5). Herein, we describe a patient with Hodgkin’s lymphoma (HL), who suffered from severe COVID-19 pneumonia and eventually died because of acute respiratory distress syndrome (ARDS) and multiorgan failure. To the best of our knowledge, this is the first reported case of COVID-19 in a HL patient who was being treated with brentuximab for relapse after allogeneic hematopoietic stem cell transplantation (alloHCT).

**CASE PRESENTATION**

In April 2020, a 55-year-old female with a medical history of classical HL diagnosed on February 2011 was diagnosed with COVID-19. Patient’s treatment history for HL included ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) at initial diagnosis (February 2011), IVE (ifosfamide, epirubicin, etoposide) as salvage chemotherapy for refractory disease (January 2012) followed by autologous hematopoietic stem cell transplantation (autoHCT) with BEAM (carmustine, etoposide, cytarabine, melphalan) as the conditioning regimen in September 2012. Nivolumab was administered for relapse after autoHCT (April 2016). She developed papillary thyroid cancer in January 2017 and was cured by thyroidectomy and radioactive iodine treatment. As salvage chemotherapy, the patient also received brentuximab + bendamustine (February 2017) and GDP (gemcitabine, dexamethasone, cisplatin) (May 2017). Partial remission (PR) was achieved and in March 2018, alloHCT was performed from HLA-matched sibling donor with Fludarabine + melphelan as the conditioning regimen. The source of stem cells was peripheral blood and GVHD prophylaxis included cyclosporine combined with methotrexate. In August 2018, severe chronic graft-versus-host-disease (GVHD) with skin and liver involvement developed. Complete remission (CR) of chronic GVHD was achieved with steroid, cyclosporine, mycophenolate mofetil and methotrexate. In November 2018, she was diagnosed with EBV associated post-transplant lymphoproliferative disorder (EBV associated PTLD) and CR was obtained after eight doses of weekly rituximab. Intravenous immunoglobulin (IVIG) 400 mg/kg/day per 3 weeks was started for acquired hypogammaglobulinemia. In November 2019, the patient developed EBV viremia and was treated with rituximab, valganciclovir and foscarnet. In January 2020, relapse of HL was diagnosed with concurrent appearance of EBV viremia (EBV DNA load 34,694 copies/ml). Brentuximab 1.8 mg/kg and DLI (CD3:5 × 106/kg) every 3 weeks was initiated. He completed three cycles of brentuximab and DLI on March 2020. After three cycles, EBV DNA load decreased to 788 copies/ml and PR was obtained. In April 2020, she presented with shortness of breath and fever. She reported a five-day history of cough. On physical examination, she was pale, her body temperature was 38.3°C and she had hypoxia, with oxygen saturation as low as 88% on room air. Lung auscultation revealed fine bibasilar crackles. Chest computed tomography (CT) showed patchy peripheral bibasilar ground glass opacities in both lungs, findings compatible with severe COVID-19 pneumonia (Figure 1). Reverse transcriptase polymerase chain reaction (PCR) assay detected the presence of SARS-CoV-2 RNA in the nasopharyngeal swab. Favipravir,
hydroxychloroquine, azithromycin and piperacillin/tazobactam were initiated. IVIG 400 mg/kg was administered. Her complete blood count (CBC) at admission showed the following: Hgb 10 g/dl, Htc 32%, total leukocyte count 4,320/mm³, neutrophil 520/mm³, lymphocyte 2,940/mm³ and platelet count 97,000/mm³. Prothrombin and activated partial thromboplastin time were normal. Serum ferritin level was 164 ug/L (23–336). Fibrinogen level was 548 mg/dl (normal range, 200 to 400) and D-Dimer was elevated (1.72 μg/ml; normal range, 0 to 0.5). Low-molecular-weight heparin (LMWH) was started. On biochemical tests, the following were abnormal: lactate dehydrogenase (LDH) 554 U/L (135–248), albumin 2.4 g/dl (3.4–4.5), pro-BNP 2,050 ng/L (70–133), ESR was elevated (48 mm/h; normal range, 2 to 20), C-reactive protein was elevated at 12.6 mg/L (normal range, 0–5) with normal procalcitonin level (0.13 ng/ml; normal range <0.5). During follow-up, she had worsening lymphopenia and her pro-BNP continued to increase. She was transferred to the ICU for respiratory failure and required invasive mechanical ventilation. Her chest X-ray revealed widespread bilateral alveolo-interstitial infiltrates (Figure 2). The patient succumbed to severe acute respiratory distress syndrome (ARDS) on the 6th day of admission to the ICU 10 days after initial admission to the hospital.

**DISCUSSION**

Centers for Disease Control and Prevention (CDC) reported that immunocompromised patients including those who underwent cancer treatment, bone marrow or organ transplantation, with a history of smoking or prolonged use of corticosteroids have the highest risk for severe COVID-19 (6). In line with the report of CDC, other reports also support that cancer patients are at a higher risk for severe illness from COVID-19, compared to the public (2). Yet, there is no clear recommendation for cancer patients to deal with the COVID-19 epidemic which makes it a challenge for oncology and hematology practice.

Abid et al. summarized recommendations for patients who develop COVID-19 while receiving conventional immunotherapy or immune-engaging therapies (7). They suggested that not critically sick COVID-19 patients should have their conventional immune checkpoint inhibitor (ICI) postponed until complete resolution of infection or wait for at least 2 weeks and immunosuppressive therapy should be considered in addition to immediate cessation of ICI in critically ill COVID-19 patients receiving ICI therapy (7). Similarly, once a patient completely recovers from COVID-19 and remains well for at least 2 weeks after recovery, the patient may be considered eligible to undergo further immune-engaging therapies including CAR T-cell therapy (7). There are few reports of HL cases with COVID-19 infection (8–11). O’Kelly et al. described COVID-19 infection in a refractory HL patient being treated with pembrolizumab (8). Simand et al. reported a HL patient incidentally diagnosed with COVID-19 when reevaluated with positron emission tomography–computed tomography (PET/CT) after the fourth cycle of chemotherapy (9). Amin et al. reported an asymptomatic HL diagnosed with COVID-19 infection during routine staging for HL using PET/CT staging (10). Boulvard Chollet et al. reported an asymptomatic COVID-19 infection diagnosed during initial staging of a HL patient (11). To our knowledge,
this is the first report of the outcome of a relapsed HL patient after alloHCT, who was being treated brentuximab and subsequently develops COVID-19.

In COVID-19 patients, T-cell responses against the SARS-CoV-2 show good correlation with IgG and IgA antibody titers. This has important implication for long-term immune response (12–14). Total lymphocytes, especially CD8+ T cells are the main inflammatory cells and play an important role in virus clearance (15). Multivariate analysis showed that post-treatment decrease in CD8+ T cells and B cells were reported as independent predictors of poor treatment outcome in COVID-19 patients (15). It has been demonstrated that CD8+ T cells tend to be an independent predictor for COVID-19 severity and treatment efficacy (16). In our patient, lymphopenia deepened during follow-up and the patient did not respond to treatment.

CD30 is expressed in the medullary of the thymus gland on a subset of activated T cells (both CD4+ and CD8+) and B cells (17). A soluble form of CD30 has been found to be elevated in the serum of patients with HL. CD30 blockade compromises the CD4+ T-cell mediated immune system (18). A recent report suggested that brentuximab with/without DLI is an effective salvage therapy for relapse of HL irrespective of pretransplant use of brentuximab (19). We described an HL patient who relapsed after alloHCT and in whom PR was achieved after three cycles of brentuximab and DLI. Cancer and its treatment can compromise the ability of the cancer patients to contain COVID-19 infection. In immunocompromised patients with COVID-19 infection, the likelihood of lethality is higher (20, 21).

Studies support that lymphopenia is a specific risk factor for adverse outcomes from COVID-19 (15). This has led some experts to recommend critical re-evaluation of the need for drugs that inhibit B cells, such as anti-CD20 monoclonal antibodies, during the pandemic (22). There is no clear recommendation about the use of brentuximab during the COVID-19 pandemic. Brentuximab has activity on T-lymphocytes and in a phase I/II study, common adverse events of brentuximab reported included lymphopenia in 80%, neutropenia in 65% and leukopenia in 65% of patients (23). Infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in brentuximab treated patients (23). It is recommended to closely monitor patients during brentuximab for bacterial, fungal, or viral infections. In our index case, we think that history of autoHCT, chemo-immunotherapy, alloHCT, EBV associated PTLD, chronic GVHD and immunosuppressive therapy. Abid MA. reported that a sustained immune response occurs in response to viral infections comprising of B-cells, CD4+, and CD8+ T-cells (25). In our index case, aforementioned factors which result in immunosupression and the recent use of brentuximab which causes lymphopenia and compromises the CD4 T-cell mediated immune system resulted in severe disease including pneumonia and ARDS related to COVID-19 infection. The prevention and protection measures to minimize the probability of being exposed to SARS-CoV-2 are very important especially in highly immunosuppressive patients. As a whole, cancer is an immunocompromised state, and many cancer treatments can further compromise the immune system. This is the first report of COVID-19 infection in a HL patient, who was treated with brentuximab for relapse after alloHCT.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Bakirkoy Dr. Sadi Konuk Research Training Hospital. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

All authors collected data, wrote, and revised the article. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We would like to acknowledge all healthcare providers who fight against the COVID-19 pandemic worldwide.
REFERENCES

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. Research T: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med (2020) 382:727–33. doi: 10.1056/NEJMoa2001017
2. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol (2020) 21:355–7. doi: 10.1016/S1470-2045(20)30096-6
3. Martino R, Ránila E, Rabella N, Muñoz JM, Peyret M, Portos JM, et al. Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis (2003) 36:1–8. doi: 10.1086/344899
4. Hakki M, Rattray RM, Prus RD. The clinical impact of coronavirus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. J Clin Virol (2015) 68:1–5. doi: 10.1016/j.jcv.2015.04.012
5. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discovery (2020) 10:783–91. doi: 10.1158/2159-8290.CD-20-0422
6. Centers for Disease Control and Prevention. People who are at higher risk for COVID-19 Disease and Unexposed Individuals.
7. Abid MB, Mughal M, Abid MA. Coronavirus Disease 2019 (COVID-19) and Respiratory virus infections in adults with hematologic malignancies: a prospective study. Clin Infect Dis (2003) 36:1–8. doi: 10.1086/344899
8. O’Kelly B, McGetrick P, Angelov D, Fay M, McGinty T, Cotter AG, et al. Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2. Br J Haematol (2020) 190:e1–3. doi: 10.1111/bjh.16798
9. Simand C, Bund C, Guiffroy B, Chaban V, Herbrecht R. Incidental Discovery of a COVID-19 Infection on a Reevaluation FDG PET/CT in a Patient Treated for Hodgkin Lymphoma. Clin Nucl Med (2020) 45:644–6. doi: 10.1097/RLU.000000000003144
10. Amin R, Grinblat L, Husain M. Incidental COVID-19 on PET/CT imaging. CMAJ (2020) 192:E631. doi: 10.1503/cmaj.200831
11. Boulevard Chollet XLE, Romero Robles MG, Garrastachú P, Cabrera Villegas A, Albornoz Almada MC, Colletti PM, et al. 18F-FDG PET/CT in Hodgkin Lymphoma With Unsuspected COVID-19. Clin Nucl Med (2020) 45:652–3. doi: 10.1097/RLU.000000000003143
12. Grifoni A, Weiskopf D, Ramirez SJ, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell (2020) 181:1489–501. doi: 10.1016/j.cell.2020.05.015
13. Weiskopf D, Schnitz KS, Raadsehn MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol (2020) 5:eabd2071. doi: 10.1126/sciimmunol.abd2071
14. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature (2020) 587:270–4. doi: 10.1038/s41586-020-2598-9
15. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect (2020) 82:2176–9. doi: 10.1016/j.jinf.2020.06.025
16. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest (2020) 130:2620–9. doi: 10.1172/JCI13724
17. Romagnani P, Annunziato F, Manetti R, Mavilia C, Lasagni L, Manuelli C, et al. High CD30 ligand expression by epithelial cells and Hassal’s corpuscles in the medulla of human thymus. Blood (1998) 91:3323–32. doi: 10.1182/blood.V91.9.3323
18. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology (2006) 118:143–52. doi: 10.1111/j.1365-2567.2006.02354.x
19. Bazarbachi A, Boumendil A, Finel H, Mohsy M, Castagna L, Blaise D, et al. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer (2019) 125:90–8. doi: 10.1002/cncr.31755
20. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol (2020) 6:1108–10. doi: 10.1001/jamaoncol.2020.0980
21. Lewis MA. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19. N Engl J Med (2020) 382:2285. doi: 10.1056/NEJMmp2006588
22. von Lilienfeld-Toal M, Vehreschild JJ, Cornely O, Pagano L, Compagno FEHA Infectious Disease Scientific Working Group, et al. Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases. Leukemia (2020) 34:1487–94. doi: 10.1038/s41375-020-0832-y
23. Ogura M, Tobinai K, Hatake K, Ishizawa U, Uike N, Uchina T, et al. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci (2014) 105:840–6. doi: 10.1111/cas.12435
24. Sharma A, Bhatt NS, St Martin A, Abid MB, Bloomquist J, Chemaly RF, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol (2021) 8:e285–93. doi: 10.1016/S2352-3026(20)30429-4
25. Abid MA, Nunley L, Abid MB. Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline. Front Immunol (2020) 11:1294. doi: 10.3389/fimmu.2020.01294

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.